Amphastar Pharmaceuticals (AMPH) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
1 Jun, 2026Opening remarks and agenda
Meeting opened by CFO William Peters, with Dr. Mary Luo acting as chairperson.
Introduction of board members, executive officers, and key management in attendance.
Outside counsel, independent auditor, and inspector of election introduced.
Agenda included election of directors, ratification of auditor, advisory votes on executive compensation, and frequency of future advisory votes.
Board and executive committee updates
Three Class I directors nominated for re-election to serve until 2029.
Board recommended voting in favor of all proposals on the agenda.
Shareholder proposals
Proposals included election of directors, ratification of auditor, advisory vote on executive compensation, and advisory vote on frequency of future compensation votes.
Latest events from Amphastar Pharmaceuticals
- Branded and biosimilar launches, led by BAQSIMI and Primatene MIST, drive growth and margin expansion.AMPH
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue up 5% to $183.9M, margin expansion, and BAQSIMI® milestone achieved.AMPH
Q2 2026 - Transitioning to proprietary drugs, expanding R&D, and targeting major product launches next year.AMPH
16th Annual East Coast IDEAS Conference - Proprietary pipeline growth and product launches drive revenue and innovation momentum.AMPH
Jefferies Global Healthcare Conference 2026 - Branded growth, pipeline launches, and R&D drive long-term value and innovation.AMPH
Barclays 28th Annual Global Healthcare Conference - BAQSIMI® and new launches drive 2026 outlook amid margin and legacy product pressures.AMPH
Q4 2025 - Strong BAQSIMIⓇ growth and pipeline expansion offset legacy declines; margins pressured.AMPH
Q3 2025 - Q2 2024 revenue up 25% to $182.4M, net income up 45%, led by BAQSIMI® and high-margin products.AMPH
Q2 2024 - Baqsimi and Primatene Mist drive growth as focus shifts to complex branded and biosimilar drugs.AMPH
Barclays 27th Annual Global Healthcare Conference